Last updated on November 2019

Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin


Brief description of study

This is a study of ADI-PEG 20 (pegylated arginine deiminase), an arginine degrading enzyme versus placebo in patients with malignant pleural mesothelioma. Malignant pleural mesothelioma have been found to require arginine, an amino acid. Thus the hypothesis is that by restricting arginine with ADI-PEG 20, the malignant pleural mesothelioma cells will starve and die.

Clinical Study Identifier: NCT02709512

Find a site near you

Start Over

Mayo Clinic

Phoenix, AZ United States
  Connect »

University of Chicago

Chicago, IL United States
  Connect »

Henry Ford Hospital

Detroit, MI United States
  Connect »

Mayo Clinic

Rochester, MN United States
  Connect »

MD Anderson Cancer Center

Houston, TX United States
  Connect »

Addenbrooke's Hospital

Cambridge, United Kingdom
  Connect »

Southampton General Hospital

Southampton, United Kingdom
  Connect »

Scunthorpe General Hospital

Scunthorpe, United Kingdom
  Connect »

Wansbeck General Hospital

Ashington, United Kingdom
  Connect »

Velindre Cancer Centre

Cardiff, United Kingdom
  Connect »

Edinburgh Cancer Centre

Edinburgh, United Kingdom
  Connect »

Austin Health

Heidelberg, Australia
  Connect »